Development of a Customizable Hepatic Arterial Tree and Particle Transport Model for Use in Treatment Planning
- PMID: 33829118
- PMCID: PMC8023303
- DOI: 10.1109/trpms.2018.2842463
Development of a Customizable Hepatic Arterial Tree and Particle Transport Model for Use in Treatment Planning
Abstract
Optimal treatment planning for radioembolization of hepatic cancers produces sufficient dose to tumors for control and dose to normal liver parenchyma that is below the threshold for toxicity. The non-uniform distribution of particles in liver microanatomy complicates the planning process as different functional regions receive different doses. Having realistic and patient-specific models of the arterial tree and microsphere trapping would be useful for developing more optimal treatment plans. We propose a macrocell-based growth method to generate models of the hepatic arterial tree from the proper hepatic artery to the terminal arterioles supplying the capillaries in the parenchyma. We show how these trees can be adapted to match patient values of pressure, flow, and vessel diameters while still conforming to laws controlling vessel bifurcation, changes in pressure, and blood flow. We also introduce a method to model particle transport within the tree that accounts for vessel and particle diameter distributions and show the non-uniform microsphere deposition pattern that results. Potential applications include investigating dose heterogeneity and microsphere deposition patterns.
Keywords: dosimetry; liver radioembolization; particle transport; treatment planning; vascular modeling.
Figures






Similar articles
-
Computer modeling of yttrium-90-microsphere transport in the hepatic arterial tree to improve clinical outcomes.Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):631-7. doi: 10.1016/j.ijrobp.2009.06.069. Epub 2009 Nov 10. Int J Radiat Oncol Biol Phys. 2010. PMID: 19910131
-
The low hepatic toxicity per Gray of 90Y glass microspheres is linked to their transport in the arterial tree favoring a nonuniform trapping as observed in posttherapy PET imaging.J Nucl Med. 2014 Jan;55(1):135-40. doi: 10.2967/jnumed.113.126839. Epub 2013 Dec 2. J Nucl Med. 2014. PMID: 24296766
-
A hepatic dose-toxicity model opening the way toward individualized radioembolization planning.J Nucl Med. 2014 Aug;55(8):1317-22. doi: 10.2967/jnumed.113.135301. Epub 2014 Jun 5. J Nucl Med. 2014. PMID: 24904111
-
Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan.Q J Nucl Med Mol Imaging. 2011 Apr;55(2):168-97. Q J Nucl Med Mol Imaging. 2011. PMID: 21386789 Review.
-
Dosimetry for radiopharmaceutical therapy.Semin Nucl Med. 2014 May;44(3):172-8. doi: 10.1053/j.semnuclmed.2014.03.007. Semin Nucl Med. 2014. PMID: 24832581 Free PMC article. Review.
Cited by
-
Personalized Dosimetry for Liver Cancer Y-90 Radioembolization Using Computational Fluid Dynamics and Monte Carlo Simulation.Ann Biomed Eng. 2020 May;48(5):1499-1510. doi: 10.1007/s10439-020-02469-1. Epub 2020 Jan 31. Ann Biomed Eng. 2020. PMID: 32006268 Free PMC article.
-
A proof-of-concept study of the in-vivo validation of a computational fluid dynamics model of personalized radioembolization.Sci Rep. 2021 Feb 16;11(1):3895. doi: 10.1038/s41598-021-83414-7. Sci Rep. 2021. PMID: 33594143 Free PMC article.
-
A mesh-based model of liver vasculature: implications for improved radiation dosimetry to liver parenchyma for radiopharmaceuticals.EJNMMI Phys. 2022 Apr 13;9(1):28. doi: 10.1186/s40658-022-00456-0. EJNMMI Phys. 2022. PMID: 35416550 Free PMC article.
-
Approaches to vascular network, blood flow, and metabolite distribution modeling in brain tissue.Biophys Rev. 2023 Aug 18;15(5):1335-1350. doi: 10.1007/s12551-023-01106-0. eCollection 2023 Oct. Biophys Rev. 2023. PMID: 37974995 Free PMC article. Review.
-
Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models.Semin Radiat Oncol. 2020 Jan;30(1):68-76. doi: 10.1016/j.semradonc.2019.08.005. Semin Radiat Oncol. 2020. PMID: 31727302 Free PMC article. Review.
References
-
- Memon K et al., “Yttrium 90 Microspheres for the Treatment of Hepatocellular Carcinoma,” Multidisciplinary Treatment of Hepatocellular Carcinoma, Recent Results in Cancer Research, vol 190. Vauthey JN, Brouquet A, Ed. Springer, Berlin, Heidelberg, 2013, pp. 207–224 - PubMed
-
- Dezarn WA, et al., "Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies." Medical physics, vol. 38 no. 8 pp. 4824–4845, August. 2011. - PubMed
-
- Therasphere USA Package Insert Rev. 14. Biocompatibles UK Ltd., a BTG International group company. [Online]. Available: https://www.btg-im.com/BTG/media/TheraSphere-Documents/PDF/TheraSphere-P..., Accessed on: Dec. 19, 2017
-
- Walrand S et al., “A hepatic dose-toxicity model opening the way toward individualized radioembolization planning.” J. Nucl. Med, vol. 55, no. 8, pp. 1317–1322, Aug. 2014. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources